CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Fabian Mueller,Jule Taubmann,Simon Voelkl,Laura Bucci,Christina Bergmann,Michael Aigner,Artur Wilhelm,Tobias Rothe,Ioanna Minopoulou,Johannes Knitza,Soraya Kharboutli,Silvia Spoerl,Ingrid Vasova, Dagmar Werner,Hannah Reimann,Sascha Kretschmann,Dimitrios Mougiakakos,Gerhard Kroenke,Georg Schett,Andreas Mackensen

BLOOD（2023）

引用 0|浏览7

暂无评分

摘要

Background: CD19-targeting chimeric antigen receptor (CAR) T cells are highly efficient in B cell malignancies. However, CD19 CAR T cells also target autoreactive B cells that trigger autoimmune diseases (AID) including systemic lupus erythematosus (SLE), idiopahtic inflammatory myositis (IIM) and systemic sclerosis (SSc). Achieving long-term remission in AID with standard therapy remains challenging and usually necessitates long-term treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要